EAU 2021 | Benefits of circulating miRNAs for follow-up of patients with seminoma

Matthew Murray, MB, BChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, talks on the history of circulating microRNA as a follow-up tool for the management of malignant germ-cell tumors, and comments on patient perspectives, in particular of patients with seminoma. Dr Murray describes how assessment of disease response of seminoma is challenging to monitor, requiring multiple CT scans, and highlights how circulating miRNA could be used as an alternative method of monitoring disease response, thus reducing the need for CT scans. Dr Murray also talks on how the use of circulating miRNA can benefit both patients and clinics. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.